Littérature scientifique sur le sujet « Fluorouracil – Analyse »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Fluorouracil – Analyse ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Fluorouracil – Analyse"
Kadziauskienė, Aistė, Ernesta Strelkauskaitė, Eglė Mockevičiūtė, Rimvydas Ašoklis, Eugenijus Lesinskas et Leopold Schmetterer. « Changes in macular thickness after trabeculectomy with or without adjunctive 5-fluorouracil ». Acta medica Lituanica 24, no 2 (17 juillet 2017) : 93–100. http://dx.doi.org/10.6001/actamedica.v24i2.3489.
Texte intégralEngelman, Dan, Michel Moreau, Antonia Lepida, Yasmine Zaouak, Marianne Paesmans et Ahmad Awada. « Metastatic breast cancer and pseudocirrhosis : an unknown clinical entity ». ESMO Open 5, no 3 (juin 2020) : e000695. http://dx.doi.org/10.1136/esmoopen-2020-000695.
Texte intégralThomas, Ritty Ann, et Vasim Ismail Patel. « A comparative analysis between intralesional 5-fluorouracil versus surgical excision with intralesional triamcinalone acetonide in keloid excision ». International Journal of Otorhinolaryngology and Head and Neck Surgery 6, no 5 (21 avril 2020) : 904. http://dx.doi.org/10.18203/issn.2454-5929.ijohns20201684.
Texte intégralZhang, Cong, Hongpeng Liu, Bin Ma, Yongxi Song, Peng Gao, Yingying Xu, Dehao Yu et Zhenning Wang. « The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer : A Meta-Analysis ». Disease Markers 2017 (2017) : 1–11. http://dx.doi.org/10.1155/2017/9202676.
Texte intégralIzyumov, Mikhail Sergeevich, Viktor Viktorovich Bulynin, Andrey Mikhailovich Bobrovskih et Olga Gennadevna Deryaeva. « Comparative Assessment of Morphological Changes in the Pleura and Lung Tissue after Pleurodesis with Various Solutions in the Experiment ». Journal of Experimental and Clinical Surgery 15, no 2 (24 juin 2022) : 147–53. http://dx.doi.org/10.18499/2070-478x-2022-15-2-147-153.
Texte intégralMohan, Ambikavathy, et Chandan Kumar. « Clinical profile and management of breast cancer in women in a rural based tertiary care hospital our experience ». International Surgery Journal 4, no 2 (25 janvier 2017) : 697. http://dx.doi.org/10.18203/2349-2902.isj20170216.
Texte intégralSimon, Ole, Georg Beyer, Ujjwal Mahajan et Julia Mayerle. « Pankreaskarzinom 2018 – reif für personalisierte Therapiekonzepte ? » TumorDiagnostik & ; Therapie 40, no 03 (avril 2019) : 180–83. http://dx.doi.org/10.1055/a-0870-8867.
Texte intégralChen, Xiaorong, Weibing Leng, YuWen Zhou, Yongyang Yu, Wenjian Meng, Peng Cao, Ziqiang Wang et Meng Qiu. « Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer : study protocol for a single-arm, open-label phase II trial ». BMJ Open 13, no 1 (janvier 2023) : e062659. http://dx.doi.org/10.1136/bmjopen-2022-062659.
Texte intégralRaj, Ben, et Madhan Shankar S. R. « Analysis Of Anticancer Activity And Its Molecular Interaction Mechanism Of Withanone, An Active Ingredient Of Withania Somnifera Using Molecular Docking ». International Journal of pharma and Bio Sciences 11, no 6 (30 novembre 2021) : 35–41. http://dx.doi.org/10.22376/ijpbs/lpr.2021.11.6.l35-41.
Texte intégralOrtega-García, María Belén, Alberto Mesa, Elisa L. J. Moya, Beatriz Rueda, Gabriel Lopez-Ordoño, Javier Ángel García, Verónica Conde et al. « Uncovering Tumour Heterogeneity through PKR and nc886 Analysis in Metastatic Colon Cancer Patients Treated with 5-FU-Based Chemotherapy ». Cancers 12, no 2 (7 février 2020) : 379. http://dx.doi.org/10.3390/cancers12020379.
Texte intégralThèses sur le sujet "Fluorouracil – Analyse"
Švobaitė, Rūta. « Phénotypage et génotypage de l'activité de la dihydropyrimidine déshydrogénase chez des patients atteints de tumeurs solides avec métastases : Pharmacocinétique de la capécitabine ». Montpellier 1, 2009. http://www.theses.fr/2009MON13513.
Texte intégralÁvila, Paulo Henrique Marcelino de. « Ação da formulação mucoadesiva contendo Bidens pilosa L (Asteraceae) sobre a mucosite intestinal induzida por 5- fluorouracil em camundongos ». Universidade Federal de Goiás, 2013. http://repositorio.bc.ufg.br/tede/handle/tede/5059.
Texte intégralApproved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2016-01-07T08:24:25Z (GMT) No. of bitstreams: 2 Dissertação - Paulo Henrique Marcelino de Ávila - 2013.pdf: 2780705 bytes, checksum: b65c3f939421d3e023fe329d0423cacf (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Made available in DSpace on 2016-01-07T08:24:25Z (GMT). No. of bitstreams: 2 Dissertação - Paulo Henrique Marcelino de Ávila - 2013.pdf: 2780705 bytes, checksum: b65c3f939421d3e023fe329d0423cacf (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Previous issue date: 2013-08-27
Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq
The gastrointestinal mucositis is a side effect caused by anti-cancer chemotherapy. Among the drugs used in antineoplastic therapy 5-fluorouracil (5-FU) deserves special attention since the incidence of intestinal mucositis is 80% on treated patients. Despite many studies on intestinal mucositis induced by chemotherapy has been carried out, there aren't effective methods for treating intestinal mucositis, only palliative measures. Moreover, several studies reported anti-inflammatory and immunomodulatory activity of Bidens Pilosa L (BPL). Objective: To investigate the action of BPL in intestinal mucositis induced by 5-FU in mice. Methods: in this study, male Swiss mice were given doses of BPL (75, 100 and 125 mg / kg) and vehicle formulation administered orally (gavage) for 6 days, while doses of 5-FU (200 mg / kg ) were administered (intraperitoneal) from the 4th to 6th day (except in the groups treated with vehicle and formulation of BPL). On day 7, the mice were euthanized and the portion instestinal of each animal was extracted to perform the histomorformetria; expression analysis of Bax, Bcl2 p53 and Ki67 by immunohistochemistry analysis of the inflammatory process through the activity of the enzyme myeloperoxidase (MPO), and evaluation lipid peroxidation by determination of levels malondialdehyde (MDA). It is importantly to note that only the dose of BPL 100 mg/kg which showed better results in the analysis weight and histomorphometric , was chosen to make the immunohistochemistry, MDA and MPO assays.Results:The doses of BPL 75, 100 and 125 mg / kg showed reduce damage triggered by 5-FU in the intestinal mucositis. However the dose of 100 mg / kg was presented the best results in terms of reduction in body mass, as well as morphometric and histological changes induced by 5-FU. Furthermore it was found that treatment with only 3 doses of BPL (75, 100 and 125 mg / kg) caused no toxicological change. It was also found that the expression rate between Bax and Bcl2 were lower in the 100 mg / kg of BPL. Moreover, the dose of 100 mg / kg of BPL showed proliferative effect with increased expression of Ki67 and reduction of inflammatory infiltrate and lipid peroxidation intestinal tissue Conclusion: The results demonstrated that BPL reduced overall damage by 5-FU in intestinal mucositis induced in mice.
A mucosite intestinal (MI) é um efeito colateral causada pela quimioterapia anti-câncer. Dentre os medicamentos utilizados na terapia antineoplásica, o 5 fluorouracil (5-FU) se destaca por causar uma incidência de mucosite intestinal de 80% nos pacientes tratados. Apesar de muitos estudos sobre a mucosite intestinal induzida por quimioterapia terem sido realizados, ainda não existem métodos eficazes para o seu tratamento, havendo apenas medidas paliativas. Nesse contexto, o uso de plantas medicinais como a Bidens Pilosa L (Asteraceae) (BPL) se torna uma alternativa promissora em virtude da sua atividade anti-inflamatória e imunomoduladora. Objetivo: Investigar a ação da BPL na mucosite intestinal induzida por 5-FU em camundongos. Métodos: Neste estudo, camundongos machos Swiss receberam as doses da formulação de BPL (75, 100 ou 125 mg/kg) ou veículo da formulação de BPL que foram administradas por via oral (gavagem) durante 6 dias, enquanto que as doses de 5-FU (200 mg/kg) foram administradas do 4º ao 6º dia, (exceto nos grupos tratados apenas com formulação de BPL e veículo).No 7º dia, os camundongos foram eutanasiados e a porção intestinal de cada animal foi extraída para realização da histomorformetria; análise da expressão de Bax, Bcl2 p53 e Ki67 por imunohistoquímica; análise do processo inflamatório através da atividade da enzima mieloperoxidase (MPO); e avaliação da peroxidação lipídica pela determinação dos níves de malondialdeído (MDA). É importante destacar que apenas a dose de BPL de 100 mg/kg foi a que apresentou melhores resultados na análise ponderal de peso e histomorfométrica, foi escolhida para fazer os ensaio de imunohistoquímica, MDA e MPO. Resultados: As doses de BPL de 75, 100 e 125 mg/kg mostraram reduzir o dano desencadeado pelo 5-FU na mucosite intestinal. Entretanto a dose de 100 mg/kg foi a que apresentou melhores resultados quanto a redução de massa corporal, assim como as alterações morfométricas e histológicas provocadas pelo 5-FU. Além disso foi verificado que o tratamento apenas com as 3 doses de BPL (75, 100 e 125 mg/kg) não provocou alterações toxicológicas. Também foi constatado que a taxa de expressão entre Bax e Bcl2 foi menor na dose de 100 mg/kg. Ademais, a dose de 100 mg/kg de BPL apresentou efeito proliferativo com aumento da expressão de Ki67, e redução de infiltrado inflamatório e peroxidação lipídica do tecido intestinal. Conclusão: Os resultados demonstraram que a BPL reduziu de modo geral os danos provocados pelo 5-FU na mucosite intestinal induzida em camundongos.
Oliveira, Suilane Coelho Ribeiro. « Estudo de fase II de substituição do 5-FU por capecitabina no esquema de quimio-radioterapia em pacientes com carcinoma de células escamosas do canal anal ». Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/5/5155/tde-01042015-105449/.
Texte intégralBackground: Squamous cell carcinoma (SCC) of the anal canal is an uncommon malignancy accounting for 1-5% of intestinal tumors; however, its incidence has been increasing. Treatment for stage II and III anal canal SCC is infusional 5-fluorouracil associated with mitomycin and radiotherapy, since 1974. More convenient treatments for patients are needed. Methods: Patients with SCC of anal cancer T2-4N0M0 or T (any) N1-3M0, with good performance status, normal blood, and renal function were treated with capecitabine 825 mg/m2 bid during radiotherapy associated with a single dose of mitomycin 15 mg/m2 on day 1. Primary objective was local control rate at 6 months determined by clinical examination and radiological assessment. Sample size was calculated using Fleming single stage design. Results: From november/2010 to february/2014 51 patients were initially included, however 43 patients were assessed. Seventeen patients (39.5%) were stage II, 11 patients (25.6%) stage IIIA, and 15 patients (34.9%) stage IIIB. Four patients (9.3%) were HIV-positive, while 39 (90.7%) were HIV-negative. Median follow-up was 23.1 months. Among patients who finished the treatment and were reevaluated at 6 months 3 patients (7%) presented partial response, 37 patients (86%) had complete response, and 3 patients developed progression of the disease (7%). Regarding grade 3-4 toxicities, 10 patients (23.2%) had grade 3 radiodermitis, 3 patients (6.9%) had grade 3-4 thrombocytopenia, 5 (11.6%) had grade 3 lymphopenia, 1 patient (2.3%) had grade 3 vomiting, 2 patients (4.6%) had grade 3 diarrhea and 3 patients (6.9%) had grade 3 leukopenia. One HIV+ patient had septic shock, pneumonia, herpetic encephalitis and macrophage activation syndrome. Colostomy rate was 18.6%. Conclusions: Capecitabine and mitomycin with radiotherapy seem to be a safe treatment for SCC of the anal cancer, with a complete response rate in 6 months of 86%
NOBILI, STEFANIA. « Analisi dell'espressione di geni coinvolti nella resistenza al 5-fluorouracile nel carcinoma colorettale ». Doctoral thesis, 2002. http://hdl.handle.net/2158/779872.
Texte intégralBendová, Petra. « Stanovování metylací v promotorových oblastech genů řídících metabolismus 5 - fluorouracilu ». Master's thesis, 2015. http://www.nusl.cz/ntk/nusl-353840.
Texte intégralAnderson, Nicole Marie. « Generation of Mouse Models of Human Hematopoietic Disease and their Use to Analyze Hematopoietic Development and Function ». Thesis, 2012. http://hdl.handle.net/1807/33872.
Texte intégralLABBOZZETTA, Manuela. « Analisi dei polimorfismi dei geni codificanti per l’enzima UDP-glucuronosiltrasferasi (UGT) e per l’enzima diidropirimidina deidrogenasi (DPD), correlati a maggiore tossicità in seguito a trattamento, rispettivamente, con Irinotecano e con 5-Fluorouracile in soggetti con tumore colon rettale (CRC) ». Doctoral thesis, 2012. http://hdl.handle.net/10447/94713.
Texte intégralLABBOZZETTA, Manuela. « ANALISI DEI POLIMORFISMI DEI GENI CODIFICANTI PER L'ENZIMA UDP-GLUCURONILTRANSFERASI (UGT) E PER L'ENZIMA DIIDROPIRIMIDINA DEIDROGENASI (DPD), CORRELATI A MAGGIORE TOSSICITA' IN SEGUITO A TRATTAMENTO, RISPETTIVAMENTE, CON IRINOTECANO E CON 5-FLUOROURACILE IN SOGGETTI CON TUMORE COLON RETTALE (CRC) ». Doctoral thesis, 2012. http://hdl.handle.net/10447/105211.
Texte intégralLivres sur le sujet "Fluorouracil – Analyse"
Grant, Warren, et Martin Scott-Brown. Principles of oncogenesis. Sous la direction de Patrick Davey et David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0322.
Texte intégralChapitres de livres sur le sujet "Fluorouracil – Analyse"
Staib, L., K. H. Link, W. D. Harzer, A. Käsbohrer, V. Liebig et H. G. Berger. « Adjuvante Therapie des Kolonkarzinoms mit 5-FU/Folinsäure/Levamisol : Überlegenheit in der Kosten-Nutzen Analyse der Multicenterstudie FOGT-1 / Adjuvant Chemotherapy in Colon Cancer with 5-Fluorouracil, Folinic Acid and Levamisole : Superiority in Cost-Efficacy Analysis of the FOGT-1 Multicenter Trial ». Dans Deutsche Gesellschaft für Chirurgie, 847. Berlin, Heidelberg : Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56458-1_301.
Texte intégralRichards, Evelleen. « Comparative Analysis of the Controversy : Vitamin C, 5-Fluorouracil and Interferon ». Dans Vitamin C and Cancer : Medicine or Politics ?, 192–215. London : Palgrave Macmillan UK, 1991. http://dx.doi.org/10.1007/978-1-349-09606-0_9.
Texte intégralTanaka, Tomoaki. « Quantitative Analysis of the Enzymes Associated with 5-Fluorouracil Metabolism in Prostate Cancer Biopsies ». Dans Methods in Molecular Biology, 301–5. Totowa, NJ : Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-163-5_25.
Texte intégralFouad, Damiri, Yahya Bachra, Grouli Ayoub, Amine Ouaket, Ahmed Bennamara, Noureddine Knouzi et Mohammed Berrada. « A Novel Drug Delivery System Based on Nanoparticles of Magnetite Fe3O4 Embedded in an Auto Cross-Linked Chitosan ». Dans Chitin and Chitosan - Physicochemical Properties and Industrial Applications [Working Title]. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.94873.
Texte intégralActes de conférences sur le sujet "Fluorouracil – Analyse"
Cao, Yuqi, Zhangwei Huang, Jiani Chen, Pingjie Huang, Weiting Ge, Dibo Hou et Guangxin Zhang. « Analysis and Characterization of 5-Fluorouracil based on Terahertz Spectroscopy ». Dans Clinical and Translational Biophotonics. Washington, D.C. : OSA, 2020. http://dx.doi.org/10.1364/translational.2020.jtu3a.6.
Texte intégralGift, Alan D., Chetan S. Shende, Frank E. Inscore et Stuart Farquharson. « Analysis of chemotherapy drug 5-fluorouracil and its metabolites by surface-enhanced Raman spectroscopy ». Dans Optics East, sous la direction de Brian M. Cullum. SPIE, 2004. http://dx.doi.org/10.1117/12.579353.
Texte intégralShrestha, Shikshya, Steve Offer et Robert B. Diasio. « Abstract 5487 : Functional analysis of rare dihydropyrimidine dehydrogenase variants relevant to 5-fluorouracil toxicity ». Dans Proceedings : AACR 106th Annual Meeting 2015 ; April 18-22, 2015 ; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5487.
Texte intégralMa, Chenhui, Alexandru Almasan et Evren Gurkan-Cavusoglu. « Abstract 225 : Computational analysis of 5-fluorouracil antitumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model ». Dans Proceedings : AACR Annual Meeting 2021 ; April 10-15, 2021 and May 17-21, 2021 ; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-225.
Texte intégralSmid, Kees, Erik Meijer, Thang V. Pham, Inge de Reus, Sander R. Piersma, Godefridus J. Peters et Connie R. Jimenez. « Abstract 572 : Proteomics analysis of the effect of fluorouracil (5FU) and 5FU/leucovorin (LV) on colorectal cancer (CRC) in patients ». Dans Proceedings : AACR 106th Annual Meeting 2015 ; April 18-22, 2015 ; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-572.
Texte intégralQuaglia, Alberto, Nikhil Aggarwa, Mark McPhail et Kevin Monahan. « PWE-053 Meta-analysis of tumour microsatellite-instability, as a predictor of response to fluorouracil-based adjuvant chemotherapy for colon cancer ». Dans British Society of Gastroenterology Annual Meeting, 17–20 June 2019, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-bsgabstracts.377.
Texte intégralŽivković Radojević, Marija, Neda Milosavljević, Slađana Aćimović Talijan, Tatjana B. Miladinović, Aleksandar Miladinović et Miloš Grujić. « Challenges in radiotherapy planning in patients with synchronous rectal and prostate cancer and hip prosthesis ». Dans 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.209zr.
Texte intégralKobunai, Takashi, Ayako Nakamura, Mamoru Nukatsuka, Kazuhiko Hayashi et Teiji Takechi. « Abstract 991 : Integrated analysis of gene expression, DNA copy number, and CpG island methylation of 5-fluorouracil-resistant human gastric cancer cell lines. » Dans Proceedings : AACR 104th Annual Meeting 2013 ; Apr 6-10, 2013 ; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-991.
Texte intégralYip, Adrian Y. S., Wings T. Loo et Louis W. C. Chow. « Abstract 2686 : Analysis of cardiac markers on patients receiving 5-fluorouracil, epirubicin, cyclophosphamide with concurrent celecoxib (FEC-C) neoadjuvant therapy for locally advanced breast cancer ». Dans Proceedings : AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010 ; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2686.
Texte intégralAljohani, Hanadi G., Gehan A. Hegazy, Ali M. El-Halawany, Aliaa A. Alamoudi, Ghada M. A. Agabnoor et Ahmed M. Al-Abd. « Abstract 305 : Combination analysis for the potential chemomodulatory effects of mansorin-A and its naphthoquinone derivative (mansonone-G) to 5-fluorouracil against liver cancer cells ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-305.
Texte intégralRapports d'organisations sur le sujet "Fluorouracil – Analyse"
Chen, Chen, Peng Chen, Xia Liu et Hua Li. Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients with Retinal Detachment. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, août 2021. http://dx.doi.org/10.37766/inplasy2021.8.0117.
Texte intégral